Brazil’s health regulator authorizes Biomm to conduct phase 3 trials of anti-Covid drug

Trials will be conducted in 35 centers and will involve 612 Covid-19 diagnosed patients who are hospitalized and requiring oxygen support.

RIO DE JANEIRO, BRAZIL - Biomm pharmaceutical company announced it has been authorized by the Brazilian Health Regulatory Agency (ANVISA) to begin phase 3 clinical trials in Brazil of the drug leronlimab, to be used against Covid-19.

The goal of the drug is to prevent the disease from evolving into a more severe condition that requires invasive mechanical ventilation.

Leronlimab is a biological drug and acts to prevent an excessive response from the immune system of patients infected with the novel coronavirus, thereby reducing the overproduction of inflammatory cytokines, also known as "cytokine storm."

According to the drugmaker, this inflammatory . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?